FDA Orange Book · active-ingredient family
Vasopressin
Vasopressin is approved as 4 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:VASOPRESSIN IN SODIUM CHLORIDE 0.9% · NDA 217766
4
Brand (NDA)
10
Generics (ANDA)
16
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VASOPRESSIN IN SODIUM CHLORIDE 0.9%RLD×3 | LONG GROVE PHARMS | NDA 217766 | — | Jul 11, 2024 | |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9%RLD×2 | BAXTER HLTHCARE CORP | NDA 217569 | — | Sep 29, 2023 | |
| VASOPRESSINRLD×2 | AM REGENT | NDA 212593 | — | Aug 03, 2020 | |
| VASOSTRICTRLD×6 | PH HEALTH | NDA 204485 | AP | Apr 17, 2014 |
Generic (ANDA) products (10)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VASOPRESSIN | SANDOZ | ANDA 212068 | AP | May 06, 2026 | |
| VASOPRESSIN | SANDOZ | ANDA 212069 | AP | May 06, 2026 | |
| VASOPRESSIN×2 | DR REDDYS | ANDA 213988 | AP | May 08, 2024 | |
| VASOPRESSIN×2 | GLAND | ANDA 216963 | AP | Feb 09, 2024 | |
| VASOPRESSIN | CIPLA | ANDA 217987 | AP | Dec 06, 2023 | |
| VASOPRESSIN | FRESENIUS KABI USA | ANDA 213206 | AP | May 26, 2023 | |
| VASOPRESSIN | EUGIA PHARMA | ANDA 214314 | AP | Aug 15, 2022 | |
| VASOPRESSIN | AMNEAL | ANDA 212944 | AP | Aug 05, 2022 | |
| VASOPRESSIN | AMPHASTAR PHARMS INC | ANDA 211857 | AP | Jul 18, 2022 | |
| VASOPRESSIN | EAGLE PHARMS | ANDA 211538 | — | Dec 15, 2021 |
Listed patents (16)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9744209 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9375478 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9744239 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9687526 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9750785 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 10010575 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9981006 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9974827 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9968649 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9962422 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9925234 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 9925233 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 12186362 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 9919026 | Jan 30, 2035 | in 8 yr 9 mo | Product |
| 9937223 | Jan 30, 2035 | in 8 yr 9 mo | U-1857 |
| 12447190 | Sep 27, 2044 | in 18 yr 7 mo | Product |
Vasopressin — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

